MDXG MiMedx Group Inc.

MiMedx Files Definitive Proxy Materials

MiMedx Files Definitive Proxy Materials

MARIETTA, Ga., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with its upcoming 2019 annual meeting of shareholders (“Annual Meeting”). The meeting is scheduled to be held on August 31, 2020 at 10:00 a.m. Eastern Time at . Shareholders as of the record date, 5:00 p.m. Eastern Time on July 14, 2020, are entitled to notice of, and to vote at, the Annual Meeting.

In light of public health concerns regarding the coronavirus (COVID-19) outbreak, the Annual Meeting will be conducted in a virtual format only to assist in protecting the health and well-being of our shareholders, directors and employees and to provide access to our shareholders regardless of geographic location.

The Company is mailing the definitive proxy statement (the “Proxy Statement”) and accompanying proxy card for the 2019 annual meeting of shareholders to its shareholders. A free copy of the Proxy Statement and other relevant documents that the Company files with the SEC may be obtained through the SEC’s website at or at the Company’s website at .

Contact:

Hilary Dixon

Investor Relations & Corporate Communications

770.651.9066

EN
03/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Enters into Exclusive Distribution Agreement with Summit Produc...

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products Agreement expands offering to include additional sheet, particulate and flowable products MARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Summit Products Group (“Summit”) to distribute three innovative, 510(k) cleared products that complement the Company’s leading Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plu...

 PRESS RELEASE

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX® Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the 15th anniversary of EPIFIX and AMNIOFIX, the Company’s placental allografts used in wound care and surgical recovery settings. “We are thrilled to mark the 15th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovatio...

 PRESS RELEASE

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®...

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel Company Continues to Broaden Leading Wound Product Offering MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States. RegenKit®-Wound Gel is an autologous platelet-rich plasma (PRP) and autologous thrombin serum (ATS) wound gel that removes iron-laden red blood cells, while concentrating essential growth factors,...

 PRESS RELEASE

MIMEDX Announces Publication in the Journal of Inflammation Focused on...

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the latest addition to its industry-leading body of scientific and clinical evidence supporting the use of its dehydrated human amnion chorion membrane (DHACM...

 PRESS RELEASE

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”) Publication Adds to Large Compendium of Evidence for MIMEDX’s Leading Product Portfolio Trial Enrollment Ongoing MARIETTA, Ga., Nov. 13, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial (“RCT”) designed to...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch